# Ipamorelin Dosage Research: Doses, Routes, and Half-Life in Studies > Ipamorelin dosage in the research literature — the doses, routes, and durations actually studied in humans and animals. Research context only; no human dosing recommendations. A study-by-study record of the doses and routes researchers used — described as research context, never as instructions. ## The gist This page lists the ipamorelin doses that *researchers* used in published studies. It is a record of what was given to which animal or person and how — not a how-to, not a recommendation, and not a protocol to copy. There is no approved human dose for ipamorelin, because it is approved for nothing. The pattern across the literature: human studies used intravenous (into-the-vein) dosing in tightly controlled hospital settings; animal studies used a mix of under-the-skin, into-the-belly, and IV routes. A key practical number is the half-life — about two hours in people, meaning the drug clears fairly quickly [2]. The popular at-home "CJC-1295 + ipamorelin" subcutaneous routine has **no** peer-reviewed human dosing basis and is described below only as the anecdotal community practice it is. Doses appear here strictly to show the evidence base. ## Doses used in human studies Two human studies define the dosing record, and both used the intravenous route under controlled conditions. The 1999 PK/PD study gave single IV infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes to healthy men (eight per dose level), establishing dose-proportional kinetics and the ~2-hour half-life [2]. The 2014 Phase 2 ileus trial gave 0.03 mg/kg IV twice daily for up to seven days to bowel-resection patients [3]. Both were clinician-administered in a hospital. Neither establishes a self-administration dose, and the trial that tested a real-world clinical outcome did not show benefit [3]. ## Doses used in animal studies Animal dosing spans several routes and is where most efficacy signals come from. The rat bone-growth study used subcutaneous ipamorelin at 18, 90, and 450 µg/day, split three times daily for 15 days [4]. A separate rat bone-mineral study used 0.5 mg/kg/day by continuous subcutaneous osmotic minipump over 12 weeks. Rat postoperative-ileus work used 0.1–1 mg/kg IV repeated four times daily. The most recent study, the 2024 ferret cachexia model, used 1–3 mg/kg intraperitoneally [5]. These are research doses in defined models — they do not translate to a human regimen. ## Routes studied and half-life Ipamorelin has been studied intravenously (human PK and clinical trials; rodent efficacy), subcutaneously (rodent bone and body-composition studies, and the dominant route in community use), intranasally (rodent PK, ~20% bioavailability), and intraperitoneally (rodent and ferret studies) [2] [4] [5]. It is not orally bioavailable; only engineered ipamorelin-derived analogs show meaningful oral uptake. The terminal half-life is approximately two hours in healthy human volunteers given IV doses, with clearance 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is a single discrete pulse peaking about 40 minutes (0.67 h) after dosing [2]. The dedicated [how long does ipamorelin stay in your system](/half-life) page works through what that half-life means in practice. ## How much cjc-1295 ipamorelin should i take The question "how much cjc-1295 ipamorelin should i take" has no evidence-based answer, because no peer-reviewed human dosing study of the combination exists. The strongest combination evidence is a single animal (mouse) muscle-tension result that a 2026 review explicitly limits to animal data [15]. Community "stack" protocols pair the two subcutaneously, but those regimens have no controlled-trial basis and are anecdotal, not recommended. This site documents the research record and does not provide a dose. There is no studied human dose to report. ## How to reconstitute cjc-1295 ipamorelin 5mg Research-supply ipamorelin (and CJC-1295) is shipped as a lyophilized — freeze-dried — powder, either the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling. As peptides, both degrade with heat and repeated freeze-thaw, so reconstituted solution is generally kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction and not a dosing guide. Because there is no approved human use, no labeled reconstitution-to-dose procedure exists; specific "5 mg" mixing ratios circulated in community guides are not validated by any controlled study [3]. --- A tolerability-first console read of the ipamorelin literature — the reported side effects, the water-retention question, and the half-life logged plainly, the single failed human trial and the blank long-term-safety line kept in view; the 'md' names a reading lens, never a clinic, and nothing here is dosed, prescribed, or sold.